U.S. Launches Ebola Vaccine Trial
2 women got the inoculation, which is only being tested for safety at this point
By Steven Reinberg
THURSDAY, Sept. 4, 2014 (HealthDay News) -- Two women have been given an experimental Ebola vaccine as the U.S. National Institutes of Health launches a much-anticipated trial to combat the often-lethal virus that has plagued four West African nations.
The women, ages 39 and 27, are the first people to receive the vaccine, which had previously been tested only in monkeys, ABC News reported.
The fast-tracked clinical trial will test the safety of the vaccine and will include 20 men and women ages 18 to 50. No one will be infected with the disease. The vaccine was developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and drug maker GlaxoSmithKline.
Human testing of the vaccine was expedited due to West Africa's Ebola outbreak that has killed more than 1,900 people.
"There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection," NIAID Director Dr. Anthony Fauci said in a statement.
In a related matter, drug maker Johnson & Johnson said Thursday that it will seek to "fast-track" the development of what is called a promising new combination vaccine against Ebola. The start of the trial is scheduled for early 2015.
U.S. and global health officials on Wednesday underscored the need for greater resources -- both medical and financial -- to fight the Ebola outbreak in West Africa. The spread of the disease is outpacing efforts to control it, it could pose a global threat and will cost at least $600 million to contain it, officials said.
"This is not an African disease. This is a virus that is a threat to all humanity," Gayle Smith, special assistant to President Barack Obama and senior director at the U.S. National Security Council, told reporters during a news briefing, the Associated Press reported.
The highly virulent disease is spreading faster than health workers in Guinea, Liberia, Nigeria and Sierra Leone can manage, Dr. Tom Kenyon, director of the U.S. Centers for Disease Control and Prevention's Center for Global Health, said during the briefing.